Swiss company Episurf Medical picked up a European CE Mark for its knee implant device called the Episealer Femoral Condyle, slated to hit shelves in the fall.
The Episealer device is a small knee implant, tailored to each patient, that grows within the bone to fix damaged cartilage.
Episurf CEO Nina Bake said the company is in the 1st stage of commercialization, and the product will roll out in phases, according to a statement.
"This new approval, in combination with a recent 70 million SEK rights issue and signed distribution contracts in Switzerland and Poland, puts us in a strong position for our product launch this fall," Bake said in prepared remarks.
Episealer is the company’s 2nd commercial product, and is still being evaluated in an ongoing clinical trial.